Please assess the completion status of the following clinical trial:

Trial Title: Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be included if they are presenting for elective cardiac surgery using cardiopulmonary bypass and are 180 days of age or less.~Exclusion Criteria:~Sensitivity to ATIII product (Thrombate, Grifols, Los Angeles, CA)~* Known inherited or acquired coagulation defect~* Current or prior treatment with pro-or anticoagulant medication within past 30 days (except aspirin or a single dose of heparin, e.g. for catheterization)~* Known central venous thrombosis~* Recent (30 days) transfusion with hemostatic blood products (fresh-frozen plasma, platelets, cryoprecipitate, whole blood)~* wt less than 3000g

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 180 Days
- Healthy Volunteers: f

Study Arms:
- Antithrombin III (Type: ACTIVE_COMPARATOR): Product- Antithrombin III is derived from pooled human plasma~ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)~a.
- Placebo (Type: PLACEBO_COMPARATOR): placebo (normal saline)

Based on this trial design, predict the completion outcome and termination type (if applicable).